menu
    • menu
    [{"orgOrder":0,"company":"Organon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organon \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Organon","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Mushroom-Derived Biopolymer","moa":"Cervical mucus","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-bwwd","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-bwwd","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-bwwd","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Eli Lilly"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dermavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Organon","amount2":1.2,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dermavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Organon","amount2":1.2,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Organon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Organon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Organon

    Menu

    Organon

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves VTAMA® Cream for Adults and Kids Aged 2+ with Atopic Dermatitis

                            Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.

                            Product Name : Vtama

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 16, 2024

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VTAMA® Update on FDA Review for Atopic Dermatitis Treatment

                            Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.

                            Product Name : Vtama

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 05, 2024

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Dermavant Sciences

                            Deal Size : $1,200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Organon Acquires Dermavant's VTAMA® Cream for Dermatology

                            Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.

                            Product Name : Vtama

                            Product Type : Small molecule

                            Upfront Cash : $175.0 million

                            October 28, 2024

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Dermavant Sciences

                            Deal Size : $1,200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Dermavant Sciences

                            Deal Size : $1,200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Organon Pays up to $1.2B to Acquire Dermavant and its Steroid-Free Skin Cream Vtama

                            Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.

                            Product Name : Vtama

                            Product Type : Small molecule

                            Upfront Cash : $175.0 million

                            September 18, 2024

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Dermavant Sciences

                            Deal Size : $1,200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galcanezumab

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

                            Details : Organon expanded its agreement with Eli Lilly to become the sole distributor and promoter of Emgality (galcanezumab), which is indicated for the treatment of migraine.

                            Product Name : Emgality

                            Product Type : Large molecule

                            Upfront Cash : $22.5 million

                            August 20, 2024

                            Lead Product(s) : Galcanezumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Recipient : Shanghai Henlius Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA Validates Henlius and Organon Biosimilar Filings for Prolia® and Xgeva®

                            Details : HLX14 (denosumab-biosimilar) is a fully human recombinant anti-RANKL monoclonal antibody, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                            Product Name : HLX14

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 24, 2024

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Recipient : Shanghai Henlius Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Daré Bioscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Organon’s XACIATO Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis

                            Details : Xaciato (clindamycin phosphate) vaginal gel 2% is a USFDA approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2024

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Daré Bioscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galcanezumab

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

                            Details : Under the agreement, Organon becomes the sole distributor and promoter of Emgality (galcanezumab), a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, and RAYVOW™ (lasmiditan), a first-in-class serotonin 5-HT1F receptor a...

                            Product Name : Emgality

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : Galcanezumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab-bwwd

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Samsung Bioepis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Int...

                            Details : Hadlima (adalimumab-bwwd), a biosimilar of Humira (adalimumab), is a TNF blocker indicated to treat Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa. Yusimry will be the first biologic product offered by the Cost Plus ...

                            Product Name : Hadlima

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 07, 2023

                            Lead Product(s) : Adalimumab-bwwd

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Samsung Bioepis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Daré Bioscience

                            Deal Size : $192.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (C...

                            Details : Under the agreement, Daré has the global rights to Xaciato (clindamycin phosphate vaginal gel), an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.

                            Product Name : Xaciato

                            Product Type : Small molecule

                            Upfront Cash : $10.0 million

                            October 16, 2023

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Daré Bioscience

                            Deal Size : $192.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth